drugset / Trial / NCT05736965
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute myeloid leukemia.
Timeline
- Start
- 2023-02-20
- Primary completion
- 2025-03-30
- Completion
- 2027-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Selinexor | Other / unclassified | 60 mg | Oral |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |